Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma.
|
31723000 |
2020 |
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of Potent VEGF Inhibitors for the Clinical Treatment of Glioblastoma, A Virtual Screening Approach.
|
31554364 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a second line treatment of glioblastomas, the vascular endothelial growth factor (VEGF) antibody bevacizumab is administered in combination with the TOP1 inhibitor irinotecan and glioblastoma cell levels of TIMP-1 could therefore potentially influence the efficacy of such treatment.
|
28963609 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using three glioblastoma cell-lines (U87, U251, and SNB19), the adaptation of glioblastoma cells in a 1% (hypoxia) and 20% (normoxia) oxygen microenvironment on proliferation, metabolism, migration, neurosphere formation, CD133 and VEGF expression was investigated.
|
31035344 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits relative to standard treatment.
|
31040671 |
2019 |
Childhood Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Proangiogenic cytokines such as VEGF and angiopoietin-2 (Ang-2) have high expression in glioblastoma in a cell-specific manner and not only drive tumor angiogenesis and vascular permeability but also negatively regulate T-lymphocyte and innate immune cell responses.
|
31597643 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bevacizumab, a VEGF-targeting monoclonal antibody, may trigger an infiltrative growth pattern in glioblastoma.
|
30414187 |
2019 |
Childhood Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, however, BIG1 and BIG2 knockdown significantly decreased the levels of VEGF mRNA and protein in glioblastoma U251 cells and HUVECs.
|
31199673 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, while under normoxic conditions, EGF stimulates the activation of both the PI3K and the MAPK pathways and the induction of VEGF, in glioblastoma cells, hypoxic conditions lead to the suppression of the PI3K/RhoA/C pathway and an exclusive switch to the MAPK pathway.
|
31698752 |
2019 |
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic ablation of interleukin-1 ligands or receptor in mice bearing RCAS/tv-a-induced platelet-derived growth factor B-overexpressing glioblastoma results in reduced oedema and partial restoration of the integrity of the blood-brain barrier, respectively; similar to results obtained with vascular endothelial growth factor neutralization.
|
31665239 |
2019 |
Childhood Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Glioblastoma (GB) is a hypervascular tumor with high VEGF expression which leads to development of an immuno suppressive TME.
|
31713115 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VM has been considered as one of the reasons that glioblastoma becomes resistant to anti-VEGF therapy.
|
30368528 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma.
|
30718358 |
2019 |
Childhood Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High gene expression levels of VEGFA and CXCL8 in the peritumoral brain zone are associated with the recurrence of glioblastoma: A bioinformatics analysis.
|
31788092 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, we evaluated modular peptide carrier L1 bearing CXCR4 targeting ligand for its ability to condense siRNA and facilitate endosomal escape and VEGFA gene silencing in CXCR4-expressing endothelial and glioblastoma cells.
|
31098995 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Downregulation of the miR-221/222 cluster diminished the invasion, migration, proliferation, and angiogenesis with reduced protein levels of matrix metalloproteinase-2 (MMP-2), MMP-9, and vascular endothelial growth factor in glioblastoma cells.
|
31106423 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, stellettin B blocks the expression and secretion of a major proangiogenic factor, vascular endothelial growth factor (VEGF), in glioblastoma cells.
|
30769863 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we reported a novel dual-targeting therapy for glioblastoma through simultaneous blockade of VEGF and CD47 signaling.
|
29754163 |
2018 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis.
|
30327956 |
2018 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGF mediated GDNF-induced angiogenesis in human glioblastoma.
|
30176167 |
2018 |
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The VEGF polymorphism rs833061 was strongly associated with increased risk for glioma (odds ratio = 164.85) and glioblastoma (odds ratio = 155.66), confirmed after Bonferroni correction.
|
29584591 |
2018 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bevacizumab (BEV), a humanized monoclonal antibody that blocks the effects of vascular endothelial growth factor A, has produced impressive response rates for recurrent GB and has been approved as second-line therapy.
|
29950856 |
2018 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), is approved for treatment of metastatic colorectal cancer, nonsquamous non-small-cell lung cancer, metastatic kidney cancer, and glioblastoma.
|
29574193 |
2018 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, nanohydrogel of quercetin was able to reduce significantly IL-8, IL-6, and VEGF production in pro-inflammatory conditions with interesting implications on the mechanism of glioblastoma cells drug resistance.
|
29030990 |
2018 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiogenesis mediated by vascular endothelial growth factor (VEGF) is a hallmark of glioblastoma.
|
29507055 |
2018 |